Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06137300 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety and Efficacy of Urinary Kallidinogenase for Large Artery Atherosclerosis Acute Ischemic Stroke

StatusNot Yet Recruiting
PhaseNot applicable
SponsorYi Yang
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 28, 2024 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Start date: Dec 1, 2023 to Mar 15, 2024v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Yi Yang
17 trials monitored
See all monitored trials
Stroke
3,531 trials monitored
See 153 trials at risk
The purpose of this study is to evaluate the safety and efficacy of urinary kallidinogenase treatment in patients with large artery atherosclerotic acute ischemic stroke.
Trial Details
NCT Number NCT06137300
Lead Sponsor Yi Yang
Conditions
(from sponsor)		 Acute Ischemic Stroke
Related terms Ischemic Stroke
Enrollment 986 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov